← Eichor
Study identifier: NCT04593407 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions.

Condition: Neoplasms, Colorectal  ·  Sponsor: José Carlos Marín Gabriel

PhaseNA
Planned participants376
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

EMR and ESD are both effective and safe and are associated with a very low risk of procedure related mortality when performed for colorectal laterally spreading lesions (LSL). Some kind of LSLs have a low risk of submucosal invasive carcinoma (SMIC) or these foci are found in well demarcated areas of the tumor. This is the case of the non-granular flat elevated (LSN-NG-FE) and the LSLs-G mixed subtypes. The investigators aim to assess if piecemeal EMR (the older technique) for LSLs-G mixed type \> 30 mm and LSLs-NG FE type \> 20 mm is not inferior to ESD (the new treatment) for the need of additional surgery in the mid-term.

This description comes directly from the study's public registry record.

Talk to the study team

José C. Marín-Gabriel, Assoc. Prof.  ·  +34 91 779 28 27  ·  josecarlos.marin@salud.madrid.org

Esperanza Ulloa-Márquez  ·  +34 91 779 28 27  ·  esperanza.ulloa@salud.madrid.org

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital Universitario "12 de Octubre"Madrid, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04593407